₹422.55
▲ +8.16 +1.97%
As of 27 Jul 2026 · delayed
NSE Listed
Panacea Biotec Ltd. (PANACEABIO)
Volume: 1,25,042Avg Vol 1W: 3,87,747.2Avg Vol 1M: 2,36,007.252W Range:₹292.4₹647
Key Ratios
Checked 1d agoMarket Cap₹2,655 Cr
Current Price₹422.55
Previous Close₹414.39
High / Low (52w)₹647 / ₹292.4
Volume1,25,042
Avg Vol (1W)3,87,747.2
Avg Vol (1M)2,36,007.2
Stock P/E5,417.5
Book Value₹136.19
Dividend Yield0%
ROE-2.9%
ROA-0.6%
Revenue (TTM)₹580 Cr
Revenue Growth0%
Profit Margin-0.8%
Total Debt₹15 Cr
Shares Outstanding6 Cr
Face Value₹1
EPS (TTM)₹0.08
P/B3.18
Debt / Equity0.03
50 DMA₹519.56
200 DMA₹407.53
Day change+1.97%
Price Chart
₹422.55▼ 0.49% · 1Y
2025-07-292026-07-27
20-day avg volume: 2.4L shares
Pros
- Company is almost debt-free.
- Revenue grew 30% YoY.
Cons
- Company is loss-making at the latest annual result.
- Stock trades at a high P/E of 5418.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹116 Cr | ₹147 Cr | ₹163 Cr | ₹133 Cr | ₹167 Cr | ₹141 Cr | ₹165 Cr | ₹167 Cr |
| EBITDA | ₹-19 Cr | ₹3 Cr | ₹3 Cr | ₹-27 Cr | ₹-4 Cr | ₹-20 Cr | ₹6 Cr | ₹-3 Cr |
| Net Profit | ₹-16 Cr | ₹5 Cr | ₹5 Cr | ₹-2 Cr | ₹4 Cr | ₹-14 Cr | ₹4 Cr | ₹1 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹77 Cr | ₹108 Cr | ₹580 Cr | ₹68 Cr | ₹112 Cr | ₹91 Cr | ₹99 Cr | ₹111 Cr |
| EBITDA | ₹5 Cr | ₹14 Cr | ₹-40 Cr | ₹-17 Cr | ₹-3 Cr | ₹-15 Cr | ₹-2 Cr | ₹2 Cr |
| Net Profit | ₹1 Cr | ₹10 Cr | ₹-8 Cr | ₹-12 Cr | ₹-7 Cr | ₹-16 Cr | ₹-7 Cr | ₹0 Cr |
| EPS | — | — | -1.37 | — | — | — | — | — |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹1,608 Cr | ₹1,376 Cr | ₹1,390 Cr | ₹1,178 Cr | ₹1,759 Cr | ₹1,271 Cr | ₹1,241 Cr | ₹1,290 Cr |
| Total Liabilities | ₹1,302 Cr | ₹1,028 Cr | ₹1,195 Cr | ₹1,409 Cr | ₹885 Cr | ₹431 Cr | ₹402 Cr | ₹459 Cr |
| Equity | ₹306 Cr | ₹347 Cr | ₹196 Cr | ₹-232 Cr | ₹874 Cr | ₹840 Cr | ₹838 Cr | ₹831 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹122 Cr | ₹103 Cr | ₹-22 Cr | ₹108 Cr | ₹295 Cr | ₹-420 Cr | ₹2 Cr | ₹-26 Cr |
| Investing | ₹55 Cr | ₹-5 Cr | ₹-35 Cr | ₹-48 Cr | ₹1,283 Cr | ₹430 Cr | ₹10 Cr | ₹65 Cr |
| Financing | ₹-164 Cr | ₹-101 Cr | ₹91 Cr | ₹-47 Cr | ₹-1,176 Cr | ₹-18 Cr | ₹-3 Cr | ₹-3 Cr |
| Free Cash Flow | ₹122 Cr | ₹103 Cr | ₹-22 Cr | ₹108 Cr | ₹295 Cr | ₹-420 Cr | ₹2 Cr | ₹-26 Cr |
Shareholding
Promoter 72.48% Institutions 4.56% Public 22.96%
Efficiency & Working Capital
ROCE0%
Interest Coverage-10.1
Dividend Payout—
Debtor Days47 d
Inventory Days139 d
Payable Days147 d
Cash Conversion Cycle39 d
Working Capital Days187 d
Shareholding Details
As of 2026-06-30
Promoter72.5%
FII2.3%
DII2.3%
Institutions4.6%
Public23%
Promoter Pledge0%
No. of Shareholders33,532
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.6% | 73.6% | 73.6% | 73.5% | 72.9% | 72.5% | 72.5% | 72.5% | 72.5% | 72.5% | 72.5% | 72.5% |
| FIIs | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | 1.2% | 0.8% | 1.1% | 1.4% | 1.6% | 2.3% |
| DIIs | 0% | 0% | 0.8% | 1.1% | 1.2% | 1.2% | 1.5% | 1.5% | 1.8% | 1.9% | 2% | 2.3% |
| Public | 26.1% | 26.1% | 25.3% | 25.2% | 25.6% | 26% | 24.9% | 25.2% | 24.7% | 24.3% | 24% | 23% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 48,878 | 47,091 | 46,242 | 45,513 | 39,982 | 35,446 | 33,593 | 34,256 | 33,593 | 34,597 | 32,620 | 33,532 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Dr. Rajesh Jain | Shareholding of Promoter and Promoter Group | 49% | 3.00 Cr |
| Mr. Sandeep Jain | Shareholding of Promoter and Promoter Group | 15.3% | 93,51,924 |
| Mrs. Nirmala Jain | Shareholding of Promoter and Promoter Group | 4.1% | 25,11,000 |
| First Lucre Partnership Co. | Shareholding of Promoter and Promoter Group | 3.7% | 22,55,815 |
| Massachusetts Institute Of Technology | Public Shareholding | 1.7% | 10,50,000 |
| Viral Amal Parikh | Public Shareholding | 1.5% | 8,99,341 |
| Rajesh Jain (huf) (karta : Rajesh Jain) | Shareholding of Promoter and Promoter Group | 0.3% | 2,00,000 |
| Second Lucre Partnership Co. | Shareholding of Promoter and Promoter Group | 0.1% | 57,639 |
| Sandeep Jain (huf) (karta : Sandeep Jain) | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mr. Abhey Kumar Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mr. Ashish Jain | Shareholding of Promoter and Promoter Group | 0% | 500 |
| Mrs. Meena Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mrs. Pamilla Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mr. Ankesh Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mr. Harshet Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Mrs. Priyanka Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Rajesh Jain | Chairman / Executive Director / M D / Promoter | 2025 |
| Sandeep Jain | ED / Joint MD / Promoter | 2025 |
| Ankesh Jain | WTD & Executive Director | 2025 |
| Harshet Jain | WTD & Executive Director | 2025 |
| Sanjay Trehan | Executive Director / WTD - Technical | 2025 |
| Ambika Sharma | Independent Non Exe. Director | 2025 |
| Krishan Kumar Jalan | Independent Non Exe. Director | 2025 |
| Rajesh Jain | Independent Non Exe. Director | 2025 |
| Rajender Pal Singh | Independent Non Exe. Director | 2025 |
| Venkatesh Sarvasiddhi | Independent Non Exe. Director | 2025 |
| Vinod Goel | CS / Compliance Officer / Group CFO / Head - Legal | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Vaccines | ₹96 Cr | 21.7% |
| Formulations | ₹348 Cr | 78.3% |
| Research and Development | ₹0 Cr | 0% |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Domestic | ₹79 Cr | 82.3% |
| Overseas | ₹17 Cr | 17.7% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 13 | 6 | 6 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 388 | 0 | 0 | 6 | 0 | 394 |
| 2025 | 230 | 0 | 0 | 0 | 0 | 230 |
| 2025 | 144 | 0 | 0 | 6 | 0 | 150 |
Insider / Designated-Person Trades
3 recent disclosure(s)
Dr. Rajesh JainDisposal · 2,00,000
Rajesh Jain HUFAcquisition · 2,00,000
Nosheen SheikhAcquisition · 3,000
Substantial Acquisitions (SAST)
1 disclosure(s)
NULL12/06/2026 · 2,00,000
Company Information
Incorporated1984
ChairmanRajesh Jain
AuditorSuresh Surana & Associates LLP/R & D
Investor Email[email protected]; investorgrievances@pa
📍 Ambala-Chandigarh Highway, Lalru, Punjab, 140501
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search